BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc., a leading company in radiopharmaceuticals, has announced the upcoming presentation of new data at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans, LA, from June 21-24, 2025. The presentations will highlight two oncology radiodiagnostic agents. Notably, the session titled "First Clinical Evaluation of 68Ga-LNTH-1363S, a Novel FAP-Targeting Radiopharmaceutical for PET Imaging," will be presented by Ida Sonni from the University of California, Los Angeles, on June 23, 2025. Additionally, Gyu Seong Heo from Washington University will present on the preclinical assessment of 64Cu-LNTH-1363S for FAP PET imaging in cardiovascular applications on June 24, 2025. The findings will be shared with the medical community during these sessions, contributing to advancements in radiopharmaceutical applications in oncology and cardiovascular imaging.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。